CONHIV14 - Oral Papers – Part Two - page 1

O315 Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study
Smith, C*; Ryom, L; d’Arminio Monforte, A; Reiss, P; Mocroft, A; El-Sadr, W; Weber, R; Law, M; Sabin, C; Lundgren, J
(London, UK)
O322 A clinically useful risk-score for chronic kidney disease in HIV infection
Mocroft, A*; Lundgren, J; Ross, M; Law, M; Reiss, P; Kirk, O; Smith, C; Wentworth, D; Heuhaus, J; Fux, C; Moranne, O; Morlat, P;
Johnson, M; Ryom, L (London, UK)
O324 Gender differences in HIV-positive persons in use of cardiovascular disease-related interventions: D:A:D study
Ingrid Hatleberg, C*; Ryom, L; El-Sadr, W; Mocroft, A; Reiss, P; de Wit, S; Dabis, F; Pradier, C; d’Arminio Monforte, A;
Rickenbach, M; Law, M; Lundgren, J; Sabin, C (Copenhagen, Denmark)
O332 The R263K mutation in HIV integrase that is selected by dolutegravir (DTG) may actually prevent clinically relevant
resistance to this compound
Wainberg, M*; Anstett, K; Mesplede, T; Quashie, P; Han, Y; Oliveira, M (Montreal, Canada)
O334 Genotypic tropism testing in proviral DNA to guide maraviroc initiation in aviremic subjects: 48-week analysis of the
PROTEST study
Garcia, F; Poveda, E; Jesús Pérez-Elías, M; Hernández Quero, J; Àngels Ribas, M; J. Martínez-Madrid, O; Flores, J; Crespo, M;
Gutiérrez, F; García-Deltoro, M; Imaz, A; Ocampo, A; Artero, A; Blanco, F; Bernal, E; Pasquau, J; Mínguez-Gallego, C; Pérez, N;
Aiestarán, A; Paredes, R* (Barcelona, Spain)
O421 Efavirenz (EFV) 400mg daily remains non-inferior to 600mg: 96 week data from the double-blind, placebo-controlled
ENCORE study
Carey, D* (Sydney, Australia)
O422 Effectiveness of a reduced dose of efavirenz plus 2 NRTIs as maintenance antiretroviral therapy with the guidance of
therapeutic drug monitoring
Yang, S-P; Liu, W-C; Lee, K-Y; Wu, B-R; Su, Y-C; Wu, P-Y; Zhang, J-Y; Luo, Y-Z; Sun, H-Y; Chang, S-Y; Lin, S-W; Hung, C-C* (Taipei
City, Taiwan)
O423A The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50
copies/mL
Antinori, A*; Arribas, J; Fehr, J; Girard, P-M; Horban, A; Hill, A; van Delft, Y; Moecklinghoff, C; Hill, A (Rome, Italy)
O423B Analysis of neurocognitive function and CNS endpoints in the PROTEA trial: darunavir/ritonavir with or without
nucleoside analogues
Clarke, A*; Johanssen, V; Gerstoft, J; Clotet, B; Ripamonti, D; Murungi, A; Bicer, C; Hadacek, M; Moecklinghoff, C (Brighton, UK)
O424 Rate of viral load failure over time in people on ART in the UK Collaborative HIV Cohort (CHIC) study
O’Connor, J*; Smith, C; Lampe, F; Johnson, M; Sabin, C; Phillips, A (London, UK)
O432A HIV- 1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24 subgroup analysis
Brinson, C; Lalezari, J; Latiff, G; Thompson, M; Echevarria, J; Treviño-Pérez, S; Stock, D; Joshi, S; Hanna, G; Lataillade, M* (Wallingford,
USA)
O432B Safety profile of HIV-1 attachment inhibitor prodrug BMS-663068 in antiretroviral-experienced subjects: week 24
analysis
Lalezari, J; Latiff, G; Brinson, C; Echevarria, J; Treviño-Pérez, S; Bogner, J; Stock, D; Joshi, S; Hanna, G; Lataillade, M* (Wallingford,
USA)
O434 48-week efficacy and safety and early CNS tolerability of doravirine (MK-1439), a novel NNRTI, with TDF/FTC in ART-
naïve HIV-Infected patients
Gatell, J*; Morales-Ramirez, J; Hagins, D; Thompson, M; Keikawus, A; Hoffmann, C; Rugina, S; Osiyemi, O; Escoriu, S; Dretler, R;
Harvey, C; Xu, X; Teppler, H (Barcelona, Spain)
ORAL PAPERS – PART TWO
*Indicates presenting author.
1 2,3,4,5,6,7,8,9,10,11,...14
Powered by FlippingBook